Your browser doesn't support javascript.
loading
Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao, Jing; Meisel, Jane; Guo, Yi; Nahta, Rita; Hsieh, Kung Lin; Peng, Limin; Wei, Zhimin; O'Regan, Ruth; Li, Xiaoxian.
Afiliação
  • Zhao J; Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Meisel J; Department of Hematology and Oncology, Emory University, Atlanta, GA, USA.
  • Guo Y; Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
  • Nahta R; Department of Pharmacology, Emory University, Atlanta, GA, USA.
  • Hsieh KL; Department of Pathology and Laboratory Medicine, Emory University, 1364 Clifton Road, Atlanta, GA, 30322, USA.
  • Peng L; Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
  • Wei Z; Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • O'Regan R; Department of Medicine, University of Wisconsin, Madison, WI, USA.
  • Li X; Department of Pathology and Laboratory Medicine, Emory University, 1364 Clifton Road, Atlanta, GA, 30322, USA. xli40@emory.edu.
Breast Cancer Res Treat ; 183(3): 599-606, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32715443

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Terapia Neoadjuvante Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Terapia Neoadjuvante Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2020 Tipo de documento: Article